Ferini Gianluca, Parisi Silvana, Lillo Sara, Viola Anna, Minutoli Fabio, Critelli Paola, Valenti Vito, Illari Salvatore Ivan, Brogna Anna, Umana Giuseppe Emmanuele, Ferrantelli Giacomo, Lo Giudice Gabriele, Carrubba Chiara, Zagardo Valentina, Santacaterina Anna, Leotta Salvatore, Cacciola Alberto, Pontoriero Antonio, Pergolizzi Stefano
REM Radioterapia srl, 95029 Viagrande, Italy.
Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, 98122 Messina, Italy.
Cancers (Basel). 2022 Aug 12;14(16):3909. doi: 10.3390/cancers14163909.
Purpose: To evaluate feasibility, toxicities, and clinical response in Stage IV patients treated with palliative “metabolism-guided” lattice technique. Patients and Methods: From June 2020 to December 2021, 30 consecutive clinical stage IV patients with 31 bulky lesions were included in this study. All patients received palliative irradiation consisting of a spatially fractionated high radiation dose delivered in spherical deposits (vertices, Vs) within the bulky disease. The Vs were placed at the edges of tumor areas with different metabolisms at the PET exam following a non-geometric arrangement. Precisely, the Vs overlapped the interfaces between the tumor areas of higher 18F-FDG uptake (>75% SUV max) and areas with lower 18F-FDG uptake. A median dose of 15 Gy/1 fraction (range 10−27 Gy in 1/3 fractions) was delivered to the Vs. Within 7 days after the Vs boost, all the gross tumor volume (GTV) was homogeneously treated with hypo-fractionated radiation therapy (RT). Results: The rate of symptomatic response was 100%, and it was observed immediately after lattice RT delivery in 3/30 patients, while 27/30 patients had a symptomatic response within 8 days from the end of GTV irradiation. Radiation-related acute grade ≥1 toxicities were observed in 6/30 (20%) patients. The rate of overall clinical response was 89%, including 23% of complete remission. The 1-year overall survival rate was 86.4%. Conclusions: “Metabolism-guided” lattice radiotherapy is feasible and well-tolerated, being able to yield very impressive results both in terms of symptom relief and overall clinical response rate in stage IV bulky disease patients. These preliminary results seem to indicate that this kind of therapy could emerge as the best therapeutic option for this patient setting.
评估采用姑息性“代谢引导”网格技术治疗IV期患者的可行性、毒性及临床反应。患者与方法:2020年6月至2021年12月,本研究纳入30例连续的临床IV期患者,共31个巨大病灶。所有患者均接受姑息性放疗,即在巨大病灶内以球形沉积(顶点,Vs)的方式进行空间分割高剂量放疗。Vs按照非几何排列放置在PET检查中具有不同代谢的肿瘤区域边缘。确切地说,Vs重叠了18F-FDG摄取较高(>75%SUV最大值)的肿瘤区域与18F-FDG摄取较低区域之间的界面。向Vs给予的中位剂量为15 Gy/1次分割(范围为10 - 27 Gy,分1/3次分割)。在Vs推量放疗后7天内,对所有大体肿瘤体积(GTV)进行大分割放射治疗(RT)。结果:症状缓解率为100%,3/30例患者在网格RT治疗后立即观察到,而27/30例患者在GTV照射结束后8天内出现症状缓解。30例患者中有6例(20%)观察到与放疗相关的急性≥1级毒性反应。总体临床缓解率为89%,包括23%的完全缓解。1年总生存率为86.4%。结论:“代谢引导”网格放射治疗是可行的且耐受性良好,在IV期巨大病灶患者的症状缓解和总体临床缓解率方面均能产生非常显著的效果。这些初步结果似乎表明,这种治疗方法可能成为该患者群体的最佳治疗选择。